Earnings History Data for REGENXBIO Inc. (RGNX) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

REGENXBIO Inc.

REGENXBIO Inc. is a biotechnology company. The Company focuses on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. Its products candidates include RGX-501, for the treatment of homozygous familial hypercholesterolemia which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; RGX-111, for the treatment of Mucopolysaccharidosis Type I which uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system; RGX-121, for the treatment of Mucopolysaccharidosis Type II; RGX-314, for the treatment of wet age-related macular degeneration and RGX-321, for the treatment of X-linked retinitis pigmentosa. REGENXBIO Inc. is headquartered in Rockville, Maryland.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
27-02-2024	AH		RGNX	REGENXBIO Inc.	765.90	-1.43	-1.13	-1.38	Regenxbio GAAP EPS of -$1.43 misses by $0.26, revenue of $22.21M misses by $11.8M [2/27/2024 4:51 PM]	19.89	-0.12 (-0.62%)	20.02	0.0 (0.00%)	11.83 - 25.32	919,105	700,000	26,905
Regenxbio GAAP EPS of -$1.43 misses by $0.26, revenue of $22.21M misses by $11.8M [2/27/2024 4:51 PM]
08-11-2023	AH		RGNX	REGENXBIO Inc.	694.13	-1.41	-1.44	-1.75	Regenxbio GAAP EPS of -$1.41 beats by $0.07, revenue of $28.91M beats by $3.12M [11/8/2023 4:14 PM]	16.84	0.43 (2.65%)	17.00	0.59 (3.60%)	12.82 - 25.54	776,440	570,000	5,001
Regenxbio GAAP EPS of -$1.41 beats by $0.07, revenue of $28.91M beats by $3.12M [11/8/2023 4:14 PM]
02-08-2023	AH		RGNX	REGENXBIO Inc.	825.86	-1.66	-1.26	-1.58	Regenxbio GAAP EPS of -$1.66 misses by $0.43, revenue of $19.97M misses by $14.53M [8/2/2023 4:31 PM]	17.50	-1.40 (-7.41%)	17.86	-1.04 (-5.50%)	17.02 - 35.73	708,066	280,000	3,908
Regenxbio GAAP EPS of -$1.66 misses by $0.43, revenue of $19.97M misses by $14.53M [8/2/2023 4:31 PM]
03-05-2023	AH	After the close (May 3)	RGNX	REGENXBIO Inc.	873.65	-1.53	-1.52	-1.62	Regenxbio GAAP EPS of -$1.53 misses by $0.14, revenue of $19.14M misses by $12.15M [5/3/2023 4:32 PM]	19.97	-0.26 (-1.28%)	19.25	-0.98 (-4.84%)	17.03 - 35.73	540,525	330,000	43,844
Regenxbio GAAP EPS of -$1.53 misses by $0.14, revenue of $19.14M misses by $12.15M [5/3/2023 4:32 PM]
28-02-2023	AH	After the close (Feb 28)	RGNX	REGENXBIO Inc.	959.39	-1.38	-1.48	6.67	Regenxbio GAAP EPS of -$1.38 beats by $0.05, revenue of $31.35M misses by $6.1M [2/28/2023 4:31 PM]	24.16	1.91 (8.58%)	22.30	0.05 (0.22%)	18.69 - 35.73	984,225	370,000	28,211
Regenxbio GAAP EPS of -$1.38 beats by $0.05, revenue of $31.35M misses by $6.1M [2/28/2023 4:31 PM]
03-11-2022	PM	7:30 AM ET (Nov 3)	RGNX	REGENXBIO Inc.	1,070	-1.75	-1.55	-1.37	Regenxbio GAAP EPS of -$1.75 misses by $0.26, revenue of $26.5M misses by $4.31M [11/3/2022 7:30 AM]	21.08	-3.16 (-13.04%)	24.24	0.0 (0.00%)	18.69 - 40.59	389,583	290,000	10,368
Regenxbio GAAP EPS of -$1.75 misses by $0.26, revenue of $26.5M misses by $4.31M [11/3/2022 7:30 AM] Regenxbio slumps 17% as Q3 Zolgensma royalty revenue falls, net loss widens [11/3/2022 12:21 PM] REGENXBIO Reports Third Quarter 2022 Financial Results and Recent Operational Highlights [Nov-03-22 07:05AM] REGENXBIO Presents Positive Interim Data from and the Expansion of Phase II ALTITUDE® Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery [Nov-03-22 06:30AM] REGENXBIO to Participate in Upcoming Investor Conferences [Nov-02-22 07:05AM] Regenxbio (RGNX) Reports Q3 Loss, Lags Revenue Estimates [Nov-03-22 08:45AM]
03-08-2022	AH	4:05 PM ET (Aug 3)	RGNX	REGENXBIO Inc.	1,340	-1.58	-1.43	-1.36	Regenxbio GAAP EPS of -$1.58 misses by $0.14, revenue of $32.65M beats by $5.87M [8/3/2022 4:33 PM]	34.72	0.73 (2.15%)	3.92	-0.40 (-9.26%)	18.69 - 46.46	262,698	330,000	51,552
Regenxbio to seek FDA's accelerated approval for Hunter Syndrome treatment, shares rise 8% [8/3/2022 10:02 AM] Regenxbio GAAP EPS of -$1.58 misses by $0.14, revenue of $32.65M beats by $5.87M [8/3/2022 4:33 PM] REGENXBIO Announces Intention to File a Biologics License Application Using the Accelerated Approval Pathway for RGX-121, an AAV Therapeutic for the Treatment of MPS II [Aug-03-22 07:05AM] Regenxbio (RGNX) Reports Q2 Loss, Tops Revenue Estimates [Aug-03-22 07:15PM] REGENXBIO Reports Second Quarter 2022 Financial Results and Recent Operational Highlights [Aug-03-22 04:05PM]
04-05-2022	AH	4:05 PM ET (May 4)	RGNX	REGENXBIO	1,193	-1.62	-1.29	0.00	Regenxbio GAAP EPS of -$1.79 misses by $0.49, revenue of $22.2M misses by $7.01M [5/4/2022 4:15 PM]	24.02	-4.42 (-15.52%)	28.44	0.0 (0.00%)	23.66 - 46.46	577,009	404,090	2,338
Regenxbio GAAP EPS of -$1.79 misses by $0.49, revenue of $22.2M misses by $7.01M [5/4/2022 4:15 PM] REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting [May-03-22 07:05AM] REGENXBIO to Participate in Upcoming Investor Conferences [May-04-22 07:05AM] REGENXBIO Inc.'s (NASDAQ:RGNX) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong? [May-04-22 03:39PM] REGENXBIO Reports First Quarter 2022 Financial Results and Recent Operational Highlights [May-04-22 04:05PM] Regenxbio (RGNX) Reports Q1 Loss, Misses Revenue Estimates [May-04-22 06:15PM]
01-03-2022	AH	4:05 PM ET (Mar 1)	RGNX	REGENXBIO Inc.	1,100	6.67	4.28	-1.24	Regenxbio GAAP EPS of $6.67 beats by $2.93, revenue of $398.65M beats by $142.89M [3/1/2022 4:18 PM]	29.08	2.63 (9.94%)	28.97	2.52 (9.53%)	24.09 - 46.46	559,457	420,000	270
Regenxbio GAAP EPS of $6.67 beats by $2.93, revenue of $398.65M beats by $142.89M [3/1/2022 4:18 PM] Regenxbio stock unchanged after hours despite bottom and top line beats [3/1/2022 5:19 PM] Regenxbio gains the most in five months on the launch of “5x25 strategy” [3/2/2022 2:49 PM] Acadia Healthcare (ACHC) Lags Q4 Earnings Estimates [Feb-28-22 06:35PM] REGENXBIO Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Operational Highlights [Mar-01-22 04:05PM] Regenxbio (RGNX) Q4 Earnings and Revenues Beat Estimates [Mar-01-22 05:45PM]
02-11-2021	AH	4:05 PM ET (Nov 2)	RGNX	REGENXBIO Inc.	1,560	-1.37	-0.87	0.23	Regenxbio EPS misses by $0.47, misses on revenue [11/2/2021 4:10 PM]	37.72	1.13 (3.09%)	36.59	0.0 (0.00%)	27.02 - 50.26	237,228	250,000	41,783
Regenxbio-Solid Biosciences' PDC releases white paper for AAV gene therapy development [11/2/2021 8:15 AM] Regenxbio EPS misses by $0.47, misses on revenue [11/2/2021 4:10 PM] Pathway Development Consortium Releases Draft White Paper to Facilitate AAV Gene Therapy Development [Nov-02-21 07:30AM] Can Regenxbio (RGNX) Climb 77% to Reach the Level Wall Street Analysts Expect? [Nov-02-21 11:23AM] REGENXBIO Reports Third Quarter 2021 Financial Results and Operational Highlights [Nov-02-21 04:05PM] Regenxbio (RGNX) Reports Q3 Loss, Misses Revenue Estimates [Nov-02-21 06:45PM] REGENXBIO inc (RGNX) Q3 2021 Earnings Call Transcript [Nov-03-21 03:01AM]
09-08-2021	AH	4:05 PM ET (Aug 9)	RGNX	REGENXBIO Inc.	1,370	-1.36	-1.08	-0.91	Regenxbio EPS misses by $0.37, beats on revenue [8/9/2021 4:27 PM]	31.34	-1.15 (-3.55%)	32.19	-0.31 (-0.95%)	25.93 - 50.26	457,934	340,000	2,789
Regenxbio EPS misses by $0.37, beats on revenue [8/9/2021 4:27 PM] REGENXBIO Reports Second Quarter 2021 Financial Results and Operational Highlights [Aug-09-21 04:05PM] Regenxbio (RGNX) Reports Q2 Loss, Misses Revenue Estimates [Aug-09-21 06:05PM] REGENXBIO inc (RGNX) Q2 2021 Earnings Call Transcript [Aug-09-21 11:30PM]
05-05-2021	AH	4:05 PM ET (May 5)	RGNX	REGENXBIO Inc.	1,470	-1.20	-1.13	-1.08	Regenxbio EPS beats by $0.02, misses on revenue [5/5/2021 4:08 PM]	34.68	2.22 (6.84%)	34.68	0.0 (0.00%)	25.93 - 50.26	602,063	240,000	2,696
REGENXBIO, Inc. to Host Earnings Call [May-05-21 02:30PM] REGENXBIO Reports First Quarter 2021 Financial Results and Operational Highlights [May-05-21 04:05PM] Regenxbio Inc. (RGNX) Q1 2021 Earnings Call Transcript [May-06-21 12:31AM] Regenxbio (RGNX) Reports Q1 Loss, Misses Revenue Estimates [May-05-21 07:15PM] REGENXBIO to Present at Upcoming Investor Conferences [May-06-21 04:05PM]
01-03-2021	AH	4:05 PM ET (Mar 1)	RGNX	REGENXBIO Inc.	1,690	-1.24	1.11	-0.72	Regenxbio EPS misses by $1.13, misses on revenue [3/1/2021 4:11 PM]	41.54	-0.97 (-2.28%)	40.90	-1.61 (-3.79%)	20.03 - 50.26	250,861	408,903	167
Regenxbio EPS misses by $1.13, misses on revenue [3/1/2021 4:11 PM] Regenxbio Inc. (RGNX) Q4 2020 Earnings Call Transcript [Mar-01-21 08:31PM] Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates [Mar-01-21 05:25PM] Recap: Regenxbio Q4 Earnings [Mar-01-21 04:58PM] REGENXBIO Reports Fourth Quarter and Full-Year 2020 Financial Results and Operational Highlights [Mar-01-21 04:05PM] REGENXBIO, Inc. to Host Earnings Call [Mar-01-21 02:30PM]
04-11-2020	AH	4:05 PM ET (Nov 4)	RGNX	REGENXBIO Inc.	1,040	0.23	-0.89	-0.94	Regenxbio EPS beats by $1.14, beats on revenue [11/4/2020 4:10 PM]	29.01	-2.05 (-6.60%)	31.52	0.46 (1.48%)	20.03 - 54.97	646,686	309,956	21,639

06-08-2020	AH	4:00 PM ET (Aug 6)	RGNX	REGENXBIO Inc.	1,280	-0.91	-0.89	-0.72	Regenxbio EPS misses by $0.06, misses on revenue [8/6/2020 4:12 PM]	33.81	-0.49 (-1.43%)	33.50	-0.80 (-2.33%)	20.03 - 54.97	145,344	319,180	1,706